ReviewFrontiers in cellular and infection microbiology2026
Therapeutic opportunities of fecal microbiota transplantation in the treatment of non-alcoholic fatty liver disease.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the emerging evidence in the crosstalk between gut microbiota composition and the non-alcoholic fatty liver disease (NAFLD), the application of fecal microbiota transplantation (FMT) on patients with NAFLD has become an attractive research field. Evidence from multiple studies have proved that lean patients with NAFLD were more sensitive to FMT in both microbiomic and metabolic aspects compared to obese patients, and more benefits were observed in patients receiving allogenic FMT from lean donors compared to those receiving autologous FMT, possibly due to the benefits derived from the successful engraftment of donor's microbiota post FMT. However, it has been observed from the clinical practice that an identified successful engraftment is not a promise of clinical efficacy in NAFLD patients. This review aims to summarize the current evidence supporting application of FMT in treatment of NAFLD. We realized that the clinical efficacy and long-term benefits of FMT on NAFLD patients warrant further investigation with more properly-designed randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.